Key Points
- Director Christopher Brown sold 9,900 shares of 908 Devices at an average price of $9.04, for proceeds of about $89,496. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Brown still held 865,559 shares, valued at roughly $7.82 million, and his ownership declined by only 1.13%.
- 908 Devices shares recently traded near $8.98, with the stock up near its 52-week high of $9.34. Analysts currently have a Hold consensus rating and a $12.00 price target.
908 Devices Inc. (NASDAQ:MASS - Get Free Report) Director Christopher Brown sold 9,900 shares of 908 Devices stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $9.04, for a total value of $89,496.00. Following the transaction, the director owned 865,559 shares in the company, valued at approximately $7,824,653.36. This represents a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
908 Devices Price Performance
Shares of 908 Devices stock opened at $8.98 on Friday. The company has a market capitalization of $339.53 million, a P/E ratio of -8.98 and a beta of 0.63. The business has a 50-day moving average of $7.81 and a two-hundred day moving average of $6.78. 908 Devices Inc. has a 1 year low of $5.03 and a 1 year high of $9.34.
Institutional Trading of 908 Devices
A number of institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of 908 Devices during the second quarter worth about $48,000. Intelligence Driven Advisers LLC acquired a new stake in 908 Devices in the 1st quarter valued at approximately $61,000. Daiwa Securities Group Inc. acquired a new stake in 908 Devices in the 2nd quarter valued at approximately $61,000. PCM Encore LLC bought a new stake in 908 Devices in the 4th quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in 908 Devices in the 2nd quarter valued at approximately $77,000. 88.06% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
MASS has been the subject of a number of research reports. Weiss Ratings cut 908 Devices from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Monday, May 11th. Wall Street Zen lowered shares of 908 Devices from a "buy" rating to a "hold" rating in a research note on Sunday, June 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $12.00.
Read Our Latest Stock Report on MASS
About 908 Devices
(
Get Free Report)
908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.
Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
